This pharmacovigilance system is crucial for identifying previously unrecognised adverse effects, monitoring the safety profile of newly licensed medications like Mounjaro, and detecting rare but serious reactions that may not have been apparent during clinical trials
Previously, the GLP-1R agonist liraglutide has been shown to attenuate EMT changes in the UUO model by inhibiting TGF-1/Smad3 and ERK1/2 signaling pathways ( The present study in kidney transplantation model also indicates that TB001 significantly enhances lipid metabolism (marked by increased CPT1A expression in TECs) and reduces PKC- and PKC- expression, thereby attenuating kidney allograft fibrosis
Despite their prevalence, the pathophysiological mechanisms underlying these conditions remain poorly understood
4 Pharmacokinetics: Demographic Covariates and Special Populations Liraglutide pharmacokinetics have been investigated in several sub-populations covering a range of demographic factors
N., Patil, N
Siemsen W, Halske C, Behrens HM, Kruger S, Becker-Pauly C, Rocken C
